Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Lulizumab pegol. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Lulizumab pegol. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Lulizumab pegol. |
| Estrone | Estrone may increase the thrombogenic activities of Lulizumab pegol. |
| Estradiol | Estradiol may increase the thrombogenic activities of Lulizumab pegol. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Lulizumab pegol. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Lulizumab pegol. |
| Mestranol | Mestranol may increase the thrombogenic activities of Lulizumab pegol. |
| Estriol | Estriol may increase the thrombogenic activities of Lulizumab pegol. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Lulizumab pegol. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Lulizumab pegol. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Lulizumab pegol. |
| Tibolone | Tibolone may increase the thrombogenic activities of Lulizumab pegol. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lulizumab pegol. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lulizumab pegol. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Lulizumab pegol. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Lulizumab pegol. |
| Zeranol | Zeranol may increase the thrombogenic activities of Lulizumab pegol. |
| Equol | Equol may increase the thrombogenic activities of Lulizumab pegol. |
| Promestriene | Promestriene may increase the thrombogenic activities of Lulizumab pegol. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Lulizumab pegol. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Lulizumab pegol. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Lulizumab pegol. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Lulizumab pegol. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Lulizumab pegol. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Lulizumab pegol. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Lulizumab pegol. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Lulizumab pegol. |
| Formononetin | Formononetin may increase the thrombogenic activities of Lulizumab pegol. |
| Estetrol | Estetrol may increase the thrombogenic activities of Lulizumab pegol. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Lulizumab pegol. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lulizumab pegol. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Lulizumab pegol. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Lulizumab pegol. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Lulizumab pegol. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lulizumab pegol. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lulizumab pegol. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Lulizumab pegol. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lulizumab pegol. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Lulizumab pegol. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Lulizumab pegol. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Lulizumab pegol. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lulizumab pegol. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lulizumab pegol. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Lulizumab pegol. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lulizumab pegol. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lulizumab pegol. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Lulizumab pegol. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lulizumab pegol. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Lulizumab pegol. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Lulizumab pegol. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Lulizumab pegol. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lulizumab pegol. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lulizumab pegol. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Lulizumab pegol. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Lulizumab pegol. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Lulizumab pegol. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Lulizumab pegol. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Lulizumab pegol. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Lulizumab pegol. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Lulizumab pegol. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Lulizumab pegol. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Lulizumab pegol. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Lulizumab pegol. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Lulizumab pegol. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Lulizumab pegol. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Lulizumab pegol. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Lulizumab pegol. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Lulizumab pegol. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Lulizumab pegol. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Lulizumab pegol. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Lulizumab pegol. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Lulizumab pegol. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Lulizumab pegol. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Lulizumab pegol. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Lulizumab pegol. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Lulizumab pegol. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Lulizumab pegol. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Lulizumab pegol. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Lulizumab pegol. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Lulizumab pegol. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Lulizumab pegol. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Lulizumab pegol. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Lulizumab pegol. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Lulizumab pegol. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Lulizumab pegol. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Lulizumab pegol. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lulizumab pegol. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Lulizumab pegol. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Lulizumab pegol. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Lulizumab pegol. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Lulizumab pegol. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Lulizumab pegol. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Lulizumab pegol. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Lulizumab pegol. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Lulizumab pegol. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lulizumab pegol. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Lulizumab pegol. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Lulizumab pegol. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Lulizumab pegol. |